Registry Intervention View

brolucizumab

Trial registrations containing the exact intervention label brolucizumab.

Exact registry label · Not reported

16 linked registrations

No aliases or equivalent products have been inferred.

Inspect all 16 registrations →

Longevity context

Topics connected by trial metadata

Vision ageing16 trials naming this intervention Biological age biomarkers1 trials naming this intervention

Safety context

4 linked registrations report posted results

This is a registry availability fact, not a safety result, comparison, or conclusion.

Understand the safety boundary →

Source records

Registered trials

CompletedNCT04543331

Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

Phase not reported · 572 planned enrolment

Countries listed: 1
Registry update: July 29, 2026

Verify in the registry →

Active Not RecruitingNCT04932980

Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD

Phase not reported · 80 planned enrolment

Countries listed: 1
Registry update: December 8, 2025

Verify in the registry →

CompletedNCT04679935

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

PHASE4 · 52 planned enrolment

Countries listed: 2
Registry update: September 26, 2025

Verify in the registry →

CompletedNCT04774926

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

PHASE4 · 122 planned enrolment

Countries listed: 1
Registry update: May 16, 2025

Verify in the registry →

TerminatedNCT04764656

Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal

Phase not reported · 81 planned enrolment

Countries listed: 1
Registry update: March 25, 2025

Verify in the registry →

RecruitingNCT04985487

Regulatory Post-Marketing Surveillance Study for Brolucizumab

Phase not reported · 3,000 planned enrolment

Countries listed: 1
Registry update: January 14, 2025

Verify in the registry →

TerminatedNCT05266495

Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting

Phase not reported · 3 planned enrolment

Countries listed: 1
Registry update: January 13, 2025

Verify in the registry →

TerminatedNCT05112835

Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice

Phase not reported · 302 planned enrolment

Countries listed: 1
Registry update: October 29, 2024

Verify in the registry →

CompletedNCT04597632

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

PHASE3 · 248 planned enrolment

Countries listed: 16
Registry update: October 9, 2024

Verify in the registry →

CompletedNCT04662944

A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections

Phase not reported · 494 planned enrolment

Countries listed: 5
Registry update: June 18, 2024

Verify in the registry →

CompletedNCT05710471

Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E

PHASE4 · 30 planned enrolment

Countries listed: 1
Registry update: May 8, 2024

Verify in the registry →

TerminatedNCT03710564

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

PHASE3 · 535 planned enrolment

Countries listed: 2
Registry update: January 30, 2023

Verify in the registry →

CompletedNCT05111743

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)

Phase not reported · 9,261 planned enrolment

Countries listed: 1
Registry update: December 21, 2021

Verify in the registry →

CompletedNCT05082415

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

Phase not reported · 9,456 planned enrolment

Countries listed: 1
Registry update: October 27, 2021

Verify in the registry →

CompletedNCT05037396

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

Phase not reported · 9,457 planned enrolment

Countries listed: 1
Registry update: October 12, 2021

Verify in the registry →

WithdrawnNCT04697953

Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)

PHASE3 · 0 planned enrolment

Countries listed: 0
Registry update: September 23, 2021

Verify in the registry →